non-Hodgkin lymphoma

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

ADC Therapeutics slumps on cancer drug safety scare

Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.

News

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

Brukinsa data raises chemo-free hope for mantle cell lymphom...

ADC Therapeutics slumps on cancer drug safety scare

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

FDA starts priority review of BeOne's Venclexta rival

Approvals extend use of Roche, AbbVie drugs in lymphoma

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

non-Hodgkin lymphoma

Editor's Picks